160 related articles for article (PubMed ID: 21570913)
1. Non-invasive imaging in experimental medicine for drug development.
Matthews PM; Rabiner I; Gunn R
Curr Opin Pharmacol; 2011 Oct; 11(5):501-7. PubMed ID: 21570913
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography molecular imaging for drug development.
Matthews PM; Rabiner EA; Passchier J; Gunn RN
Br J Clin Pharmacol; 2012 Feb; 73(2):175-86. PubMed ID: 21838787
[TBL] [Abstract][Full Text] [Related]
3. Recent applications of positron emission tomographic (PET) imaging in psychiatric drug discovery.
Zimmer L
Expert Opin Drug Discov; 2024 Feb; 19(2):161-172. PubMed ID: 37948046
[TBL] [Abstract][Full Text] [Related]
4. Receptor Occupancy Imaging Studies in Oncology Drug Development.
Burvenich IJG; Parakh S; Parslow AC; Lee ST; Gan HK; Scott AM
AAPS J; 2018 Mar; 20(2):43. PubMed ID: 29520671
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomographic imaging in drug discovery.
Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
[TBL] [Abstract][Full Text] [Related]
6. The role of imaging in proof of concept for CNS drug discovery and development.
Wong DF; Tauscher J; Gründer G
Neuropsychopharmacology; 2009 Jan; 34(1):187-203. PubMed ID: 18843264
[TBL] [Abstract][Full Text] [Related]
7. Modeling of PET data in CNS drug discovery and development.
Varnäs K; Varrone A; Farde L
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Central Nervous System Drug Development Using Molecular Imaging.
Hargreaves RJ; Hoppin J; Sevigny J; Patel S; Chiao P; Klimas M; Verma A
Clin Pharmacol Ther; 2015 Jul; 98(1):47-60. PubMed ID: 25869938
[TBL] [Abstract][Full Text] [Related]
9. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
Soares HD
Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
Lohmann S; Herold A; Bergauer T; Belousov A; Betzl G; Demario M; Dietrich M; Luistro L; Poignée-Heger M; Schostack K; Simcox M; Walch H; Yin X; Zhong H; Weisser M
Methods; 2013 Jan; 59(1):10-9. PubMed ID: 22796720
[TBL] [Abstract][Full Text] [Related]
11. The application of positron emission tomography (PET) imaging in CNS drug development.
Suridjan I; Comley RA; Rabiner EA
Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
[TBL] [Abstract][Full Text] [Related]
12. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
13. PET as a Translational Tool in Drug Development for Neuroscience Compounds.
Varrone A; Bundgaard C; Bang-Andersen B
Clin Pharmacol Ther; 2022 Apr; 111(4):774-785. PubMed ID: 35201613
[TBL] [Abstract][Full Text] [Related]
14. [Molecular imaging-based early-phase and exploratory clinical research].
Watanabe Y
Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
[TBL] [Abstract][Full Text] [Related]
15. From biomarker strategies to biomarker activities and back.
van Gool AJ; Henry B; Sprengers ED
Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
[TBL] [Abstract][Full Text] [Related]
16. [In vivo imaging of liposomal small interfering RNA (siRNA) trafficking by positron emission tomography].
Ando H; Yonenaga N; Asai T; Hatanaka K; Koide H; Tsuzuku T; Harada N; Tsukada H; Oku N
Yakugaku Zasshi; 2012; 132(12):1373-81. PubMed ID: 23208044
[TBL] [Abstract][Full Text] [Related]
17. Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
Xu Y; Miao X; Ravenstijn P; Hijzen A; Schmidt ME; Nandy P; Zhou H
Clin Transl Sci; 2020 Mar; 13(2):309-317. PubMed ID: 31642608
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule PET Tracers in Drug Discovery.
Donnelly DJ
Semin Nucl Med; 2017 Sep; 47(5):454-460. PubMed ID: 28826520
[TBL] [Abstract][Full Text] [Related]
19. Imaging in Central Nervous System Drug Discovery.
Gunn RN; Rabiner EA
Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
[TBL] [Abstract][Full Text] [Related]
20. Functional Characterization of 5-HT
Hansen HD; Mandeville JB; Sander CY; Hooker JM; Catana C; Rosen BR; Knudsen GM
J Neurosci; 2017 Nov; 37(44):10671-10678. PubMed ID: 28972127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
